REG - GlaxoSK Capital PLC GlaxoSmithKline PLC - Publication of Final Terms

GSKAnnouncement

07/05/2020 17:45

RNS Number : 3404M
  
GlaxoSmithKline Capital PLC
  
07 May 2020
  
 

 
Issued: 7 May 2020, London UK - LSE Announcement
 
 
Publication of Final Terms
 
The following final terms dated 7 May 2020 (the "Final Terms") in respect of the Notes (as defined below) are available for viewing:
GlaxoSmithKline Capital plc issue of:
 
GBP 750,000,000 1.250 per cent. Notes due 12 October 2028;
 
GBP 750,000,000 1.625 per cent. Notes due 12 May 2035; and
 
EUR 750,000,000 0.125 per cent. Notes due 12 May 2023,
 
in each case guaranteed by GlaxoSmithKline plc issued under the £20,000,000,000 Euro Medium Term Note Programme (the "Notes")
 
Copies of the Final Terms have been submitted to the UK Listing Authority's NSM submission portal via the Electronic Submission System (ESS). A copy can be viewed at:
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
 
For further information, please contact:
GlaxoSmithKline Capital plc
980 Great West Road
Brentford
Middlesex
TW8 9GS
United Kingdom
 
Enquiries:



UK Media enquiries:


David Mawdsley
Simon Steel


(020) 8047 5564
(020) 8047 3763




European Analyst/Investor enquiries:


James Dodwell
Danielle Smith


(020) 8047 2406
(020) 8047 0932



 
BASIS ON WHICH YOU MAY ACCESS THE FINAL TERMS AND BASE PROSPECTUS
Please note that the information contained in the Final Terms and the Base Prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Base Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Final Terms is not addressed. Prior to relying on the information contained in the Final Terms or the Base Prospectus you must ascertain from the Base Prospectus whether or not you are part of the intended addressees of the information contained therein. 
Your right to access this service is conditional upon complying with the above requirements.
 
 
 
 
 
 
 
 
 
 
 
 



GlaxoSmithKline plc 
Registered in England & Wales:
No. 3888792










Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS



 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
PFTBLGDUCXGDGGR